-
South Africa detected new coronavirus mutation or stronger transmission
Time of Update: 2021-10-02
According to a report on the 30th by the Chinese website of the United States, South African scientists stated in a research report that they have detected a new variant of the new coronavirus that is more spreading than the variant previously discovered in South Africa .
-
Multiple sclerosis saves the fate of CD20 antibodies
Time of Update: 2021-10-02
Unlike Gazyva, Roche's later humanized CD20 antibody Ocrevus (Ocrelizumab, second generation) is based on multiple sclerosis as the first indication.
Source: NextPharmaSecondly, when Ocrevus was first approved, it also covered the primary progressive multiple sclerosis (PPMS) patient population.
-
Takeda OX2R agonist for the treatment of sleep disorders plans to be included in breakthrough treatments
Time of Update: 2021-10-02
Retrieved Aug 26, 2021, from http://#[2] Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda's Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1).
-
Novartis CAR-T therapy second-line NHL breaks down
Time of Update: 2021-10-02
This trial called BELINDA is expected to recruit 318 B-cell NHL patients over 18 years of age who do not respond to first-line therapy or progress within 12 months of first-line therapy, and compare the effects of Kymriah with high-dose chemotherapy plus standard stem cell transplantation on event-free survival.
-
Preliminary clinical results of TCR-T cell therapy for advanced hepatocellular carcinoma are positive
Time of Update: 2021-10-02
Today, Adaptimmune Therapeutics announced at the International Liver Cancer Association 2021 annual meeting (ILCA2021) that the company’s T cell receptor (TCR)-T cell therapy was obtained in the phase 1 clinical trial ADP-A2AFP for the treatment of patients with advanced hepatocytes.
-
Featured on the cover of "Nature-Medical"!
Time of Update: 2021-10-02
In the follow-up evaluation of up to 10 months, the researchers pointed out that the median overall survival of patients after receiving treatment can reach 22.
-
The virus has the strongest spread before and after the symptoms of new crowns appear
Time of Update: 2021-10-02
American scientists wrote in the latest issue of the Journal of the American Medical Association that their new research found that people infected with the new crown virus are most infectious two days before and three days after the onset of the disease, and if the asymptomatic infection spreads , Contacts are more likely to become asymptomatic infections .
-
Enpagliflozin is recognized by the FDA as a breakthrough therapy for the treatment of heart failure with preserved ejection fraction
Time of Update: 2021-10-02
Boehringer Ingelheim (Boehringer Ingelheim) and Eli Lilly and Company (Eli Lilly and Company) today announced that the US FDA has granted Empagliflozin (English trade name Jardiance) breakthrough therapy designation for the treatment of heart failure with preserved ejection fraction (HFpEF) Adult patients .
-
A breakthrough in 40 years!
Time of Update: 2021-10-02
The paper pointed out that in the first-line treatment of advanced esophageal cancer, this is the first randomized phase 3 study to report anti-PD-1 or anti-PD-L1 therapy combined with chemotherapy compared with chemotherapy to refresh overall survival and progression-free survival .
-
JAK inhibitors on the same track have repeatedly encountered safety issues. Pfizer, AbbVie, Eli Lilly...Who can break the game first?
Time of Update: 2021-10-02
On the same day that Sanofi/Regeneron released the news, Pfizer also announced its research JAK1 inhibitor Abrocitinib head-to-head Dupixent for the phase 3 clinical JADE of moderate to severe atopic dermatitis.
-
British NICE recommends Bristol-Myers Squibb Opdivo to treat head and neck cancer
Time of Update: 2021-10-01
At that time, NICE stated that evidence collected in Opdivo’s clinical trials and through the NICE Cancer Drug Fund (CDF) showed that SCCHN patients treated with Opdivo survived compared with patients treated with one of the three therapies in the control group.
-
Researchers improve optical tissue removal method for diagnosing cancer
Time of Update: 2021-10-01
The ability to visualize cancer tumors and metastatic tissues in three dimensions can help clinicians diagnose the precise type and stage of cancer, as well as inform the best treatment methods .
-
Junshi Biological releases first-line Phase 3 study data of teriprizumab in the treatment of esophageal cancer
Time of Update: 2021-10-01
Among them, the first-line phase 3 clinical trial (JUPITER-06 study) of teriprizumab combined with chemotherapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) announced the results for the first time, which significantly improved the survival benefits of patients and is expected to become the field New standard treatment plan .
-
Nature Immunology: Rapid response signal platform provides a new way to block allergic inflammation
Time of Update: 2021-10-01
"Blocking the allergen perception pathway can provide a unique opportunity to combat type 2 immunity and relieve allergic inflammation," said Marc Rothenberg, MD, director of the Cincinnati Children's Allergy and Immunity Department and senior author of the study .
-
Cui Jie’s research team published the results of comparative viromic analysis of deep and shallow sea soft beetles
Time of Update: 2021-10-01
In order to compare the differences in virus composition of deep-sea and shallow-sea organisms, the research team also analyzed the virions of shallow-sea soft armoured animals (shrimp, crab, etc.
-
BIOPIC Bai Fan's research team and collaborators reveal the co-evolutionary characteristics of Epstein-Barr virus-positive gastric cancer tumor cells and Epstein-Barr virus
Time of Update: 2021-10-01
Comparison of the degree of methylation in EBVaGC and precancerous lesion tissues; RasGAP family gene mRNA levels decrease after EBV infection, and RAS pathway activity increasesBy integrating molecular events at different stages of tumor development, the researchers found that EBVaGCs and HD have high-frequency PI3K-Akt pathway genes (PIK3CA/B, PTEN), Wnt pathway genes (CTNNB1, GNAS) and ARID1A mutations and copy numbers Mutations, and these mutations are rare in normal gastric mucosal tissues and LD .
-
Nature Neuroscience has discovered immune system B cells in the meninges
Time of Update: 2021-10-01
Scientists were surprised to find that there are a large number of B cells and their immature progenitor cells in the outer layer of the meninges-the dura mater .
-
Science reveals how ribosomes are assembled in human cells
Time of Update: 2021-10-01
?In this study, the researchers developed a human gene editing platform for labeling ribosomal assembly factors, and established a new biochemical procedure to overcome the obstacle of extracting ribosomal precursor particles from the structural nucleoli in the nucleus .
-
Modular lipoprotein toxins transferred through outer membrane exchange target discrete cell entry pathways
Time of Update: 2021-10-01
This process is called OM exchange (OME) and is likely to be mediated by OM fusion (Figure 1A) As a cargo includes a set of SitA polymorphic toxins, which can distinguish non-clonal cells carrying compatible TraA receptors (12) In contrast, cloned cells are resistant because they contain a homologous SitI immune protein that has not been transferred .
-
Science discovers link between inflammation and pancreatic cancer development
Time of Update: 2021-10-01
Therefore, the authors predict that inflammatory cells will have a strong positive selection for KRAS mutations or other changes that stimulate ADM and limit the accumulation of damage .
